DBP International: Signed a collaboration partnership agreement with Alexavi for commercialization of Temodex®
Double Bond Pharmaceutical International AB (publ) (“DBP” or “Double Bond”) has entered into a collaborative partnership with Alexavi Ltd (“Alexavi”). This is a major step in Double Bond’s development process and marks the company’s commitment to move forward towards approval and commercialisation of Temodex® program, for the treatment of Glioblastoma. This collaboration will open up accessibility to a ground-breaking treatment paradigm in this therapeutic area.
Alexavi will be managing an Early Access to Treatment program on behalf of Double Bond to raise awareness of the treatment’s availability to physicians and patients across the globe.
Glioblastoma, the most common and aggressive malignant form of all primary brain tumours, affects glial cells and accounts for 52% of all brain tissue tumour cases and 20% of all tumours inside the skull. Approximately 250,000 patients with Glioblastomas are identified globally each year.
The current standard of care is surgery followed by radiation and chemotherapy. Double Bond’s Temodex® is a chemotherapy drug administered directly at the site of the tumour following surgical removal, in the form of a gel, thus ensuring that the therapeutic effect is felt precisely where it is needed. Temozolomide is a prodrug which destroys the tumour’s DNA and triggers the death of tumour cells.
Double Bond Pharmaceutical acquired Orphan Drug Designation for Temodex® (Temozolomide gel) from the European Medicines Agency in 2016. Whilst developing their own form of this product further (currently known as SI-053), they are making this available to physicians across the globe.
About Alexavi Ltd: www.alexavi.com/ Alexavi is a global development and commercialisation services supplier to the pharmaceutical, biotech, medical device and medicinal products industry, founded in 2021 with the aim of assisting companies of varying sizes to meet their development and commercialisation goals in a compliant, cost and time effective manner. Alexavi seeks to change the current paradigm of service provision in this sector with an emphasis on getting new treatments to patients faster.
About Early Access to Treatment program: www.alexavi.com/our-programs
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-11-2021 08:30 CET.
____________________________________________________________________
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn and Twitter!
__________________________________________________________________
Information about Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on the development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumors, in October 2015, and was granted Orphan Drug Designation status by EMA in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in the EU and globally and has a working name SI-053 in the DBP pipeline.